Astion Pharma Enrolls for Phase III trials

Astion Pharma A/S, which develops products for the treatment of skin diseases, has inititated enrollment for three Phase III clinical trials of a treatment for the inflammatory dermatological disease seborrheic dermatitis. Three studies will take place involving approximately 1200 patients with moderate to severe facial seborrheic dermatitis.Two studies will examine the treatments safety profile in short-term treatment, and the third will examine the safety profile in long-term treatment

For further information please contact:

Lars Smedegaard Andersen

Tel: +45 4333 4802

Email: lsa@astion.com

Or visit: www.astion.com.